Intravenous Mineralocorticoid Receptor Antagonist Use in Acutely Decompensated Heart Failure with Diuretic Resistance.
Administration, Intravenous
Aged
Aged, 80 and over
Bumetanide
/ administration & dosage
Canrenoic Acid
/ administration & dosage
Creatinine
/ blood
Diuresis
/ drug effects
Diuretics
/ administration & dosage
Drug Combinations
Drug Resistance
Furosemide
/ administration & dosage
Heart Failure
/ drug therapy
Humans
Hydrochlorothiazide
/ administration & dosage
Male
Mineralocorticoid Receptor Antagonists
/ administration & dosage
Potassium
/ blood
Treatment Outcome
Cardiac edema
Cardiovascular diseases
Congestive heart failure
Dyspnea
Furosemide
Potassium canrenoate
Journal
International heart journal
ISSN: 1349-3299
Titre abrégé: Int Heart J
Pays: Japan
ID NLM: 101244240
Informations de publication
Date de publication:
30 Jan 2021
30 Jan 2021
Historique:
pubmed:
19
1
2021
medline:
5
2
2021
entrez:
18
1
2021
Statut:
ppublish
Résumé
Intravenous mineralocorticoid receptor antagonists (MRAs) have been used in some centers for decades to reduce the risk of hypokalemia and boost diuresis in acutely decompensated heart failure (ADHF). We report the well-tolerated use of intravenous MRAs as a rescue procedure in 3 patients admitted for ADHF with important diuretic resistance. Undertaking trials evaluating the effect of this therapeutic strategy in ADHF could represent a promising avenue.
Substances chimiques
Diuretics
0
Drug Combinations
0
Mineralocorticoid Receptor Antagonists
0
Hydrochlorothiazide
0J48LPH2TH
Bumetanide
0Y2S3XUQ5H
Furosemide
7LXU5N7ZO5
Canrenoic Acid
87UG89VA9K
Creatinine
AYI8EX34EU
Potassium
RWP5GA015D
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM